Epidermal growth factor receptor derived peptide vaccination to prevent lung adenocarcinoma formation: An in vivo study in a murine model of EGFR mutant lung cancer

Molecular Carcinogenesis

Volumn 55, Issue 11, 2016, Pages 1517-1525

  Ebben, Johnathan D ^a   Lubet, Ronald A ^b   Gad, Ekram ^c   Disis, Mary L ^c   You, Ming ^a  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

Author keywords

cancer prevention; lung cancer; peptide vaccine

Indexed keywords

CANCER VACCINE; DOXYCYCLINE; EPIDERMAL GROWTH FACTOR RECEPTOR; HERMES ANTIGEN; L SELECTIN; ONCOPROTEIN; PEPTIDE VACCINE; TRANSCRIPTION FACTOR FOXP3; EGFR PROTEIN, HUMAN; PEPTIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER PREVENTION; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL STRUCTURE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSPOT ASSAY; FLOW CYTOMETRY; GENE OVEREXPRESSION; HISTOLOGY; IN VIVO STUDY; LUNG ADENOCARCINOMA; LUNG CARCINOGENESIS; LUNG PARENCHYMA; MOUSE; MURINE MODEL; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; SPLEEN CELL; TUMOR IMMUNITY; VACCINATION; ANIMAL; CHEMISTRY; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; HUMAN; IMMUNOLOGY; LUNG NEOPLASMS; MUTATION; PROCEDURES; TRANSGENIC MOUSE; TUMOR CELL LINE;

ANIMALS; CANCER VACCINES; CELL LINE, TUMOR; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LUNG NEOPLASMS; MICE; MICE, TRANSGENIC; MUTATION; PEPTIDES; RECEPTOR, EPIDERMAL GROWTH FACTOR; VACCINATION;

EID: 84941114100     PISSN: 08991987     EISSN: 10982744     Source Type: Journal    
DOI: 10.1002/mc.22405     Document Type: Article

References (22)

1. Lehto RH. Lung cancer screening guidelines. The nurse's role in patient education and advocacy. Clin J Oncol Nurs 2014; 18:338–342.
2. Shi Y, et al. A prospective, molecular epidemiology study of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology (PIONEER). J Thorac Oncol 2014; 9:154–162.
3. Schwartz AG, Ruckdeschel JC. Familial lung cancer: Genetic susceptibility and relationship to chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2006; 173:16–22.
4. Putila J, Guo NL. Combining COPD with clinical, pathological and demographic information refines prognosis and treatment response prediction of non-small cell lung cancer. PLoS ONE 2014; 9:e100994.
5. Hystad P, et al. Long-term residential exposure to air pollution and lung cancer risk. Epidemiology 2013; 24:762–772.
6. Raaschou-Nielsen O, et al. Lung cancer incidence and long- term exposure to air pollution from traffic. Environ Health Perspect 2011; 119:860–865.
7. Lubin JH. Studies of radon and lung cancer in North America and China. Radiat Prot Dosimetry 2003; 104:315–319.
8. Lollini PL, et al. Vaccines for tumor prevention. Nat Rev Cancer 2006; 6:204–216.
9. Rodriguez PC, et al. Clinical development and perspectives of CIMAvax EGF, Cuban vaccine for non-small-cell lung cancer therapy. MEDICC Rev 2010; 12:17–23.
10. Forde PM, Kelly RJ, Brahmer JR. New strategies in lung cancer: Translating immunotherapy into clinical practice. Clin Cancer Res 2014; 20:1067–1073.
11. Brunsvig PF, et al. Telomerase peptide vaccination in NSCLC: A phase II trial in stage III patients vaccinated after chemoradiotherapy and an 8-yr update on a phase I/II trial. Clin Cancer Res 2011; 17:6847–6857.
12. Szyszka-Barth K, et al. Actual status of therapeutic vaccination in non-small cell lung cancer. Contemp Oncol (Pozn) 2014; 18:77–84.
13. Bethune G, et al. Epidermal growth factor receptor (EGFR) in lung cancer: An overview and update. J Thorac Dis 2010; 2:48–51.
14. Politi K, et al. Lung adenocarcinomas induced in mice by mutant EGF receptors found in human lung cancers respond to a tyrosine kinase inhibitor or to down-regulation of the receptors. Genes Dev 2006; 20:1496–1510.
15. Billiau A, Matthys P. Modes of action of Freund's adjuvants in experimental models of autoimmune diseases. J Leukoc Biol 2001; 70:849–860.
16. Park KH, et al. Insulin-like growth factor- binding protein-2 is a target for the immunomodulation of breast cancer. Cancer Res 2008; 68:8400–8409.
17. Krupnick AS, et al. Quantitative monitoring of mouse lung tumors by magnetic resonance imaging. Nat Protoc 2012; 7:128–142.
18. Lee CK, et al. Impact of EGFR inhibitor in non- small cell lung cancer on progression-free and overall survival: A meta-analysis. J Natl Cancer Inst 2013; 105:595–605.
19. Disis ML, et al. A multiantigen vaccine targeting neu, IGFBP-2, and IGF-IR prevents tumor progression in mice with preinvasive breast disease. Cancer Prev Res (Phila) 2013; 6:1273–1282.
20. Akbay EA, et al. Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors. Cancer Discov 2013; 3:1355–1363.
21. Baxevanis CN, et al. HER-2/neu as a target for cancer vaccines. Immunotherapy 2010; 2:213–226.
22. Stockert E, et al. A survey of the humoral immune response of cancer patients to a panel of human tumor antigens. J Exp Med 1998; 187:1349–54.